Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol De-Lists ABI Taxol Patent Under Settlement With Ivax

Executive Summary

Bristol-Myers Squibb is de-listing the American BioSciences paclitaxel patent that threatened the continued marketing of generic versions of Taxol

You may also be interested in...



Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines

The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.

Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share

Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA

Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share

Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA

Related Content

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel